[IPO] LaMeditech "Targeting Global Beauty Market with World's First Ultra-Compact Laser"

CEO Choi Jong-seok of LaMeditech is holding a press conference in Yeouido, Seoul on the 30th to introduce the company. / Photo by LaMeditech

LaMeditech, a specialized company in beauty and medical devices based on ultra-small laser core technology (CEO Choi Jong-seok), held a press conference in Yeouido, Seoul on the 30th to announce its future business strategy following its listing on the KOSDAQ market.

CEO Choi Jong-seok introduced the company, saying, “LaMeditech has independently designed ultra-small lasers through its own research and established a diverse product lineup using this technology. We are a company with a core business strategy covering medical and beauty devices applying our proprietary core technology.”

He continued, “Through the commercialization of the industry’s only ultra-small laser technology, we aim to grow into a next-generation innovative device company spanning from the K-Beauty market to the Meditech sector, leading the global laser healthcare industry.”

The world’s first successfully commercialized ultra-small high-power laser is LaMeditech’s core technology. ▲The laser oscillator design and manufacturing technology can reduce the size by 90-95% compared to existing laser oscillators, and ▲the laser rod design and manufacturing technology shortens the growth time by about 8-10 times compared to existing laser oscillators. Due to these advantages, LaMeditech receives ODM (Original Design Manufacturer) requests from global top-tier companies for product development.

Additionally, the laser blood collection device “HandyRay series,” designed using proprietary core technology, has been selected as an innovative product by the government procurement agency. Along with global certifications such as the European CE and the US FDA, it has completed registration as a new medical technology with the Ministry of Health and Welfare in Korea, establishing a foundation for insurance reimbursement.

Representative products in the skin beauty and medical device category include professional-use devices such as “Purasel-MX” and “Purasel,” home care device “Purasel-ME,” and skin disease treatment device “CareBeam.” By the end of this year, sales from the laser skin beauty and medical device division are expected to account for about 70%, and laser blood collection devices about 30%.

LaMeditech plans to make this year the first year of full-scale business. It intends to maximize the use of new medical technology notifications and expand hospital sales through insurance fee application. The company will also confirm product reliability and stability through additional clinical trials and expand domestic and international distributors by utilizing government sales support systems.

LaMeditech recorded sales of 2.9 billion KRW last year. With the commercialization of products developed based on its proprietary technology starting this year, it expects to achieve sales of 9.2 billion KRW and an operating profit of 1 billion KRW, turning profitable. Next year, it plans to achieve sales of 14 billion KRW and an operating profit of 3.6 billion KRW.

Meanwhile, through this KOSDAQ market listing, LaMeditech plans to offer a total of 1,298,000 shares. The public offering price range is from 10,400 KRW to 12,700 KRW, aiming to raise up to 16.48 billion KRW based on the upper limit. The proceeds will be used for research and development to advance products, facility funds, and sales and marketing to expand sales channels. Subscription will be conducted over two days on the 5th and 7th of next month based on the finalized offering price, with listing scheduled for June 17. Daishin Securities is the lead underwriter.